Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAMES F PEHOUSHEK

Allopathic & Osteopathic Physicians Dermatology

NPI
1104810720
CMS profile
140595
Location
GLENDALE, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$2,702.33

80 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,502.33 79
Consulting Fee $1,200.00 1

By paying entity

PY2020 · entire year · sorted by reported total

Page 2 of 2; records 51–80 of 80 matching records. This page contains 30 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAMES F PEHOUSHEK

NPI 1104810720 · CMS profile ID 140595

Allopathic & Osteopathic Physicians / Dermatology

GLENDALE, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–80 of 80 matching records. This page contains 30 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1104810720?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAMES F PEHOUSHEK, NPI 1104810720, CMS profile ID 140595. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–80 of 80 matching records. This page contains 30 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104810720?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). JAMES F PEHOUSHEK, NPI 1104810720, CMS profile ID 140595. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–80 of 80 matching records. This page contains 30 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104810720?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
JAMES F PEHOUSHEK, NPI 1104810720, CMS profile ID 140595, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–80 of 80 matching records. This page contains 30 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1104810720?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

80 matching records · $2,702.33 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 80 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–80 of 80.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $17.0607/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741100123 CMS
PFIZER INC. $32.2107/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743232795 CMS
AbbVie Inc. $21.7606/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722072577 CMS
GENZYME CORPORATION $22.1306/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744162473 CMS
Janssen Biotech, Inc. $1,200.0006/23/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719182645 CMS
AbbVie Inc. $24.9406/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722072575 CMS
Amgen Inc. $23.0306/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741395973 CMS
AbbVie Inc. $18.6606/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722072573 CMS
LEO Pharma Inc. $22.2206/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 746686191 CMS
Novartis Pharmaceuticals Corporation $22.8905/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726073443 CMS
AbbVie Inc. $23.2105/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722072571 CMS
Novartis Pharmaceuticals Corporation $11.4805/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726073439 CMS
Amgen Inc. $23.4204/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741100119 CMS
AbbVie Inc. $22.3304/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722072569 CMS
Janssen Biotech, Inc. $12.9604/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719182651 CMS
Novartis Pharmaceuticals Corporation $11.4703/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726073433 CMS
AbbVie Inc. $23.6703/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722072567 CMS
GlaxoSmithKline, LLC. $11.1003/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738883495 CMS
Janssen Biotech, Inc. $6.1102/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719182647 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $15.9102/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737471141 CMS
AbbVie Inc. $22.5002/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722072565 CMS
GENZYME CORPORATION $15.7002/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744162457 CMS
AbbVie Inc. $22.3302/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722072563 CMS
Novartis Pharmaceuticals Corporation $24.2502/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726073428 CMS
Janssen Biotech, Inc. $17.6402/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719182649 CMS
AbbVie Inc. $23.7401/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722072561 CMS
Amgen Inc. $5.2701/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741100117 CMS
Novartis Pharmaceuticals Corporation $31.8601/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726073417 CMS
Novartis Pharmaceuticals Corporation $21.4601/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726073423 CMS
AbbVie Inc. $21.6101/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722072559 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,297.97 111
PY2020 $2,702.33 80
PY2021 $3,584.50 144
PY2022 $2,987.14 156
PY2023 $3,388.34 154
PY2024 $3,415.57 133
PY2025 $4,475.20 174

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $783.49 8
PY2025 Principal investigator $178,012.05 29
PY2024 Principal investigator $259,511.52 29
PY2023 Principal investigator $462,264.80 39
PY2022 Principal investigator $1,495,517.29 78
PY2021 Principal investigator $617,302.12 60
PY2020 Principal investigator $787,725.19 69
PY2019 Principal investigator $980,609.97 77

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

37 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $3,537.36 12/31/2025 Non-covered Recipient Entity
ADVANCED RESEARCH ASSOCIATES
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy No dispute reported 06/30/2026 1202534377
Principal investigator 1 ABBVIE INC. $2,115.00 12/04/2025 Non-covered Recipient Entity
ADVANCED RESEARCH ASSOCIATES
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202528906
Principal investigator 1 ABBVIE INC. $6,556.26 12/04/2025 Non-covered Recipient Entity
ADVANCED RESEARCH ASSOCIATES
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202528992
Principal investigator 1 ABBVIE INC. $6,237.50 11/05/2025 Non-covered Recipient Entity
ADVANCED RESEARCH ASSOCIATES
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202521961
Principal investigator 1 ABBVIE INC. $6,000.00 11/05/2025 Non-covered Recipient Entity
ADVANCED RESEARCH ASSOCIATES
A multicenter, double-blind, randomized, parallel-group, controlled study to evaluate the safety and effectiveness of ELAPR002f injectable gel in adult participants with atrophic acne scars No dispute reported 06/30/2026 1202522045
Principal investigator 1 ABBVIE INC. $9,500.00 11/05/2025 Non-covered Recipient Entity
ADVANCED RESEARCH ASSOCIATES
M21-841 NOA Volume - Mid Face US Pivotal Study No dispute reported 06/30/2026 1202523121
Principal investigator 1 ABBVIE INC. $5,038.89 11/04/2025 Non-covered Recipient Entity
ADVANCED RESEARCH ASSOCIATES
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202520437
Principal investigator 1 ABBVIE INC. $3,197.00 10/09/2025 Non-covered Recipient Entity
ADVANCED RESEARCH ASSOCIATES
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202514249
Recipient ABBVIE INC. $21.48 10/04/2025 Covered Recipient Physician A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars No dispute reported 06/30/2026 1202400487
Recipient ABBVIE INC. $329.94 10/04/2025 Covered Recipient Physician A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars No dispute reported 06/30/2026 1202400491
Recipient ABBVIE INC. $53.69 10/04/2025 Covered Recipient Physician A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars No dispute reported 06/30/2026 1202400495
Recipient ABBVIE INC. $66.00 10/04/2025 Covered Recipient Physician A Study To Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants with Atrophic Acne Scars No dispute reported 06/30/2026 1202400498
Recipient ABBVIE INC. $31.15 10/04/2025 Covered Recipient Physician A Study To Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants with Atrophic Acne Scars No dispute reported 06/30/2026 1202400503
Recipient ABBVIE INC. $125.35 10/03/2025 Covered Recipient Physician A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars No dispute reported 06/30/2026 1202400475
Recipient ABBVIE INC. $123.49 10/03/2025 Covered Recipient Physician A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars No dispute reported 06/30/2026 1202400478
Recipient ABBVIE INC. $32.39 10/03/2025 Covered Recipient Physician A Study To Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants with Atrophic Acne Scars No dispute reported 06/30/2026 1202400482
Principal investigator 1 ABBVIE INC. $2,422.28 09/17/2025 Non-covered Recipient Entity
ADVANCED RESEARCH ASSOCIATES
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202511228
Principal investigator 1 ABBVIE INC. $4,615.00 09/04/2025 Non-covered Recipient Entity
ADVANCED RESEARCH ASSOCIATES
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202509560
Principal investigator 1 ABBVIE INC. $13,112.52 09/03/2025 Non-covered Recipient Entity
ADVANCED RESEARCH ASSOCIATES
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202508070
Principal investigator 1 ABBVIE INC. $1,009.92 09/02/2025 Non-covered Recipient Entity
ADVANCED RESEARCH ASSOCIATES
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202506963
Principal investigator 1 ABBVIE INC. $6,700.00 08/06/2025 Non-covered Recipient Entity
ADVANCED RESEARCH ASSOCIATES
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202502272
Principal investigator 1 ABBVIE INC. $1,315.00 07/08/2025 Non-covered Recipient Entity
ADVANCED RESEARCH ASSOCIATES
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202497036
Principal investigator 1 ABBVIE INC. $4,479.26 07/02/2025 Non-covered Recipient Entity
ADVANCED RESEARCH ASSOCIATES
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202494155
Principal investigator 1 ABBVIE INC. $3,995.00 06/03/2025 Non-covered Recipient Entity
ADVANCED RESEARCH ASSOCIATES
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202489817
Principal investigator 1 ABBVIE INC. $11,351.76 06/03/2025 Non-covered Recipient Entity
ADVANCED RESEARCH ASSOCIATES
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202489819
Principal investigator 1 ABBVIE INC. $1,193.64 05/08/2025 Non-covered Recipient Entity
ADVANCED RESEARCH ASSOCIATES
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202484443
Principal investigator 1 ABBVIE INC. $7,996.64 05/07/2025 Non-covered Recipient Entity
ADVANCED RESEARCH ASSOCIATES
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202483469
Principal investigator 1 ABBVIE INC. $6,775.00 05/07/2025 Non-covered Recipient Entity
ADVANCED RESEARCH ASSOCIATES
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202483589
Principal investigator 1 ABBVIE INC. $1,353.50 04/24/2025 Non-covered Recipient Entity
ADVANCED RESEARCH ASSOCIATES
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202478951
Principal investigator 1 ABBVIE INC. $5,310.00 04/03/2025 Non-covered Recipient Entity
ADVANCED RESEARCH ASSOCIATES
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202470026
Principal investigator 1 ABBVIE INC. $11,920.41 04/03/2025 Non-covered Recipient Entity
ADVANCED RESEARCH ASSOCIATES
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202470253
Principal investigator 1 ABBVIE INC. $8,631.33 03/18/2025 Non-covered Recipient Entity
ADVANCED RESEARCH ASSOCIATES
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202464035
Principal investigator 1 ABBVIE INC. $3,053.52 03/13/2025 Non-covered Recipient Entity
ADVANCED RESEARCH ASSOCIATES
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202463057
Principal investigator 1 ABBVIE INC. $11,171.25 03/07/2025 Non-covered Recipient Entity
ADVANCED RESEARCH ASSOCIATES
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202459510
Principal investigator 1 ABBVIE INC. $14,103.88 03/07/2025 Non-covered Recipient Entity
ADVANCED RESEARCH ASSOCIATES
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202459514
Principal investigator 1 ABBVIE INC. $9,518.13 02/06/2025 Non-covered Recipient Entity
ADVANCED RESEARCH ASSOCIATES
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202446899
Principal investigator 1 ABBVIE INC. $5,802.00 01/22/2025 Non-covered Recipient Entity
ADVANCED RESEARCH ASSOCIATES
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202440508